Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1821 - Quality-of-life in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and FOLFIRI – Interim results of the non-interventional AIO study QoLiTrap


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Colon and Rectal Cancer


Roger von Moos


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


R. von Moos1, G. Derigs2, F. Scholten3, J. Thaler4, C. Losem5, H. Kroening6, C. Windemuth-Kieselbach7, R.D. Hofheinz8

Author affiliations

  • 1 Medical Oncology, Hospital Graubuenden, 7000 - Chur/CH
  • 2 Oncology, Hospital Frankfurt, 65929 - Frankfurt/DE
  • 3 Oncoogy, Klinikum Frankfurt Hoechst, 65929 - Frankfurt am Main/DE
  • 4 Oncology, Klinikum Wels-Grieskirchen GmbH, 4600 - Wels/AT
  • 5 Oncology, Facharztzentrum Neuss, Neuss/DE
  • 6 Oncology, Medical Practice, 39104 - Magdeburg/DE
  • 7 Biostatistics, Alcedis, Gießen/DE
  • 8 Oncology, University Hospital, Mannheim/DE


Abstract 1821


The anti-angiogenic fusion protein Aflibercept targets VEGF-A, VEGF-B and PlGF. Aflibercept in combination with FOLFIRI is approved in patients with mCRC that is resistant or has progressed after oxaliplatin-containing therapy.


QoLiTrap (AIO-LQ-0113) is an international (Austria, Germany, Switzerland) non-interventional study with a recruitment target of 1500 patients. Primary goal is to evaluate Quality-of-life (QoL) in mCRC patients treated with aflibercept + FOLFIRI using the EORTC-QLQ C30 questionnaire at baseline and before every cycle.


For this interim analysis (data cut-off: 02 March 2017) 576 patients (mean age: 64.7 ± 10 years; 65.1% male, 50.5% with documented RAS mutation, ECOG 0-1: 85.6% of patients) who completed the baseline and at least 2 post-baseline EORTC-QLQ C30 questionnaires were evaluated. Aflibercept was administered for a median number of 6 (and up to 55) cycles. Patients had a median global health score of 58.3 which decreased moderately (mean change -4.0, p 


The current interim analysis indicates that aflibercept + FOLFIRI in mCRC patients under routine conditions was accompanied by a moderate decline in global health status. Preliminary efficacy results are encouraging, also for patients pretreated with anti-EGFR antibody and/or bevacizumab, who showed a disease control rate of 73% in second line aflibercept therapy. This study is supported by Sanofi-Aventis Deutschland GmbH.

Clinical trial identification


Legal entity responsible for the study

Sanofi Aventis GmbH


Sanofi Aventis Deutschland GmbH


R. von Moos: Advisory board: Sanofi, Roche, Merck. Research grant: Amgen, Merck. G. Derigs: Advisory activities: Janssen, Roche, Clegene. F. Scholten: Advisory activities: BMS, Celgene. Honorarium: Janssen, Sanofi. Poster creation: Sanofi. R.D. Hofheinz: Advisory Board: Sanofi. Honorarium: Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.